Press "Enter" to skip to content

FDA to Accelerate the Approval of Lurbinectedin in Small Cell Lung Cancer – Targeted Oncology

admin 0
  1. FDA to Accelerate the Approval of Lurbinectedin in Small Cell Lung Cancer  Targeted Oncology
  2. FDA grants priority review to lurbinectedin for relapsed small cell lung cancer  Healio
  3. PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug  European Biotechnology
  4. PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer  BioSpace
  5. View Full Coverage on Google News

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *